LBx Bio is building a compact platform that continuously monitors molecular signals between standard clinical tests, allowing earlier detection of disease changes and directing them to confirmatory testing within existing workflows. The system integrates biomarker data, patient trajectories, and clinical context into a unified monitoring layer, aiming to improve oncology care by surfacing meaningful changes sooner. Partners are engaged to validate and deploy the technology in real-world settings.
Funding
Funding not disclosed
Founders
Product
Problem
Current clinical practice relies on infrequent centralized biomarker tests, which often miss early disease changes and delay detection of progression, especially in high‑burden cancers.
Solution
LBx Bio is creating a compact, continuous monitoring platform that measures molecular biomarkers between routine visits. The system captures real‑time biomarker signals, aligns them with individual patient trajectories and clinical context, and flags significant changes for confirmatory testing within existing workflows. By providing earlier insight into disease dynamics, the platform enables clinicians to make more timely escalation or de‑escalation decisions. Initial deployment focuses on oncology, where frequent, repeatable monitoring can improve treatment management and outcomes.
Target Audience
Primary customers are oncology clinicians and healthcare systems seeking continuous molecular monitoring to inform treatment decisions, as well as diagnostic laboratories integrating the platform into their existing testing workflows.
Features
- Miniaturized device capable of serial biomarker sampling without requiring full laboratory visits
- Integrated analytics layer that combines raw biomarker data, longitudinal patient trends, and relevant clinical parameters
- Automated alerting mechanism that routes flagged changes to confirmatory testing pathways already in use
- Cloud‑based data repository ensuring secure storage, interoperability with electronic health record systems, and real‑time clinician access
- Oncology‑focused assay panels designed for high‑burden cancers, with extensibility to other disease areas